NCT01506895 - A Phase 2 Clinical Study to Investigate Effects of Darapladib in Subjects With Diabetic Macular Edema | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions

Retinopathy, Diabetic

Interventions

DRUG

darapladib

Experimental compound 160 mg dose

DRUG

placebo

Placebo to match

Trial Locations (16)

2000

GSK Investigational Site, Sydney

2150

GSK Investigational Site, Parramatta

3002

GSK Investigational Site, East Melbourne

6009

GSK Investigational Site, Nedlands

10122

GSK Investigational Site, Turin

20132

GSK Investigational Site, Milan

20157

GSK Investigational Site, Milan

35128

GSK Investigational Site, Padua

48145

GSK Investigational Site, Münster

51109

GSK Investigational Site, Cologne

79106

GSK Investigational Site, Freiburg im Breisgau

89075

GSK Investigational Site, Ulm

Unknown

GSK Investigational Site, Glostrup Municipality

04103

GSK Investigational Site, Leipzig

1105 AZ

GSK Investigational Site, Amsterdam

3011 BH

GSK Investigational Site, Rotterdam